British Columbia Extends Biosimilar Switching To Adalimumab

Follows Launch Of Five Humira Biosimilars In Canada In February

 
• By Dave Wallace

British Columbia has expanded its biosimilar switching program to cover patients being treated with Humira in the Canadian province.

British Columbia Canada Flags
British Columbia is flying the flag for biosimilar switching in Canada • Source: Alamy

More from Biosimilars

More from Products